This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: King Abdulaziz University, University of Jeddah. Active years: 2025.
Company Filing History:
1 out of 588 
1 out of 12 Years Active: 2025
Title: The Innovative Contributions of Peter Natesan Pushparaj
Introduction
Peter Natesan Pushparaj is a notable inventor based in Jeddah, Saudi Arabia. He has made significant contributions to the field of cancer treatment, particularly in the development of compounds aimed at combating acute myeloid leukemia (AML). His innovative work has the potential to impact the lives of many patients suffering from this aggressive form of cancer.
Latest Patents
Peter Natesan Pushparaj holds a patent for a compound titled "2-(5-aminopyridin-2-yl)-N-benzylacetamides and use thereof in the treatment of acute myeloid leukemia." This patent identifies three compounds that share a common molecular template of 2-(5-(N-acylamino)pyridin-2-yl)-N-benzylacetamide. These compounds have been recognized as potential anticancer therapeutic agents, specifically targeting AML cells. Compound I, in particular, was designed to inhibit the growth of AML cells and induce cell death. It has demonstrated a dose-dependent effect on various AML cell lines, including HL-60, Mv4-11, KG-1a, and K562.
Career Highlights
Throughout his career, Peter has worked with esteemed institutions such as the University of Jeddah and King Abdulaziz University. His research and development efforts have focused on creating effective treatments for cancer, showcasing his dedication to advancing medical science.
Collaborations
Peter has collaborated with several professionals in his field, including Roaa M Alreemi and Hind A Alkhatabi. These collaborations have contributed to the success of his research and the development of his patented compounds.
Conclusion
Peter Natesan Pushparaj's innovative work in the field of cancer treatment exemplifies the impact that dedicated inventors can have on healthcare. His contributions, particularly in the development of compounds for treating acute myeloid leukemia, highlight the importance of research and collaboration in advancing medical science.